Search Tag: Hologic

2015 10 Dec

-- Aptima® HBV Quant Assay Joins Tests for HIV-1 and HCV on the Fully Automated Panther Instrument -- Hologic, Inc. has earned CE-IVD certification for its Aptima HBV Quant assay on the fully automated Panther® instrument, the Company has announced.   This assay expands the European virology menu available on the Panther system, which previously...Read more

2015 07 Dec

A high-profile conference for Boston-area women will host Marlborough-based Hologic and its 40-foot 3D MAMMOGRAPHY™ bus, a hands-on display of the latest innovation in breast cancer screening.   Hologic’s 3D MAMMOGRAPHY™ bus is a walk-through tour and information center for women to learn about a new kind of mammogram, which clinical studies have...Read more

2015 12 Nov

Co-testing could prevent more cases of invasive cervical cancer and cost the health care system less money over time, study shows Researchers presented a new clinical-economic modeling analysis this week showing that screening for cervical cancer with Pap+HPV Together™ (co-testing) using the Aptima® HPV assay (an mRNA-based HPV test) and the...Read more

2015 30 Sep

Chenoweth to Serve as Spokeswoman for National Campaign to Increase Insurance Coverage of Hologic's Genius™ 3D Mammography™ Exam -- Hologic, Inc. (Nasdaq: HOLX) announced that award-winning actress and singer  Kristin Chenoweth  will join  Steve MacMillan , the Company's Chairman, President and Chief Executive Officer, to ring the Nasdaq Opening...Read more

2015 29 Sep

Mammography providers say Hologic stands out for technology innovation, high image quality, and C-View™ dose-reduction technology Hologic, Inc. (NASDAQ: HOLX) announced that U.S. mammography providers gave Hologic and Hologic's Genius™ 3D Mammography™ exams top scores in a new study by KLAS Research, Women's Imaging 2015. Are New Technologies Delivering...Read more

2015 16 Jul

Hologic, Inc. (NASDAQ: HOLX) has commented on an important cervical cancer screening studyipublished on-line this week in  Cancer Cytopathology , a peer-reviewed journal of the American Cancer Society. The study, by researchers at Quest Diagnostics and the University of Pittsburgh Medical Center, supports current consensus guidelinesii for cervical...Read more

2015 17 Jun

BEDFORD, Mass. , / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that  David LaVance  has resigned as Chairman of the Company's Board of Directors, and notified the Board that he will not stand for re-election at the 2016 Annual Meeting of Stockholders. Steve MacMillan , Hologic's President and Chief Executive Officer, has been appointed...Read more

2015 15 Jun

BEDFORD, Mass. ,/ PRNewswire / --   Hologic, Inc. (NASDAQ: HOLX) announced that award-winning actress and singer  Kristin Chenoweth  will serve as spokesperson for a national campaign to generate awareness of Hologic's Genius 3D Mammography exam, a more accurate mammogram that has been clinically proven to reduce callbacks by up to 40 percent and...Read more

2015 29 May

Initial Proceeds from New $1.5 Billion Term Loan and $1 Billion Revolving Credit Line Used to Refinance Senior Secured Debt PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that the Company has entered into a new, five-year secured credit agreement consisting of a  $1.5 billion  senior Term Loan and a  $1 billion  revolving credit facility....Read more

2015 07 May

BEDFORD, Mass. ,  May 7, 2015 / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced today that the Company will present at two upcoming investor conferences in May: The Bank of America Merrill Lynch 2015 Healthcare Conference in  Las Vegas  on  Tuesday, May 12  at  1:40 pm Pacific Time  (PT). The UBS Global Healthcare Conference in  New York...Read more

2015 29 Apr

- Revenues of $655.5 Million Grow 4.9% on a Reported Basis, 7.2% in Constant Currency - - Company Records GAAP EPS of $0.17, Non-GAAP EPS of $0.41 - - Company Raises Full-Year Revenue and Earnings Guidance - BEDFORD, Mass. , / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced today the Company's financial results for the second...Read more

2015 16 Apr

BEDFORD, Mass. , / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) today commented on an important cervical cancer screening studyi published on-line this week in  Cancer Cytopathology , a peer-reviewed journal of the American Cancer Society. The study, by researchers at Quest Diagnostics and the University of Pittsburgh Medical Center, supports current...Read more

2015 06 Apr

BEDFORD, Mass. , / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that the Company plans to release its operating results for the second quarter of fiscal 2015 on  Wednesday, April 29, 2015 , after the market closes.  In conjunction with the release, management will host a conference call that day at  4:30 p.m. Eastern Time . Interested participants...Read more

2015 01 Apr

BEDFORD, Mass. ,/ PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued  November 23, 2010 , and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes. ...Read more

2015 26 Feb

The amount of clinical proof for the efficacy of Tomosynthesis in screening is significantly larger than the proof available in the early days of the transition from analog mammography to FFDM.  Results from studies in Europe using Tomosynthesis in population based screening and results from screening with Tomosynthesis in the USA are concordant...Read more

2014 12 Feb

Research supports the use of Hologic's lower dose 3D mammography technology and the continued use of two-views over one in breast cancer screening Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women,...Read more

2014 28 Jan

With an emphasis on improving lives, Hologic is focused on bringing the latest in diagnostic innovations to the fast growing Gulf region Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, will feature...Read more

2013 22 Nov

3D Mammography, Hologic's game-changing breast cancer screening technology, is a major focus at the largest radiology gathering in the world Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women,...Read more

2013 17 Sep

Growing number of peer-reviewed clinical publications document significant advantages of  H ologic® tomosynthesis; Now, Hologic has further advanced tomosynthesis with faster and  lower-dose options including the C-View™ software option for 2D imaging and the Affirm™  tomosynthesis biopsy procedure. Tomosynthesis is going from strength...Read more

2013 24 May

Hologic has announced that the first large-scale observational study in a U.S. clinical practice comparing breast cancer screening with Hologic's 3D mammography technology (breast tomosynthesis) with conventional 2D mammography alone showed a significant reduction in recall rates and a sizeable increase in cancer detection, particularly invasive cancer,...Read more

2013 24 May

Hologic has announced US Food and Drug Administration approval of its new C-View 2D imaging software. C-View 2D images may now be used in place of the conventional 2D exposure previously required as part of a Hologic 3D mammography (breast tomosynthesis) screening exam. C-View images are generated from the 3D tomosynthesis data acquired during...Read more

2013 17 May

Hologic  has announced its results for the second fiscal quarter ended March 30, 2013. Highlights Include: Financial: Revenues of $612.7 million, net of a $(6.4) million adjustment related to contingent revenue earned and received under Gen‐Probe Incorporated's (Gen‐Probe) collaboration agreement with Novartis. Non‐GAAP adjusted revenues...Read more

2013 09 May

Hologic has announced the publication of the final results of a large-scale prospective study comparing breast cancer screening using Hologic's 2D mammography plus tomosynthesis (Breast Tomosynthesis) with conventional 2D mammography published online in advance of print by The Lancet Oncology. The study, "Integration of 3D digital mammography with...Read more

2013 21 Mar

Breast tomosynthesis has created a lot of interest within the women’s imaging community. While the clinical benefits are becoming more apparent, the reimbursements in the U.S. are inconsistent, and it is expensive to adopt this technology. Providers want to know: Is it worth the investment? Is a positive return on investment (ROI) possible? Hologic...Read more